GlassScriptPhysician profile
Cindy Tran
NPI 1720615420
$1,488.96
in general payments reported to CMS, 2019-2025
25 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $794 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $261.27 | 2023-2025 | |
| Lilly USA, LLC | $193.13 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $172.25 | 2023-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $102.66 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $100.89 | 2023-2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $69.24 | 2025 | |
| Merck Sharp & Dohme LLC | $56.91 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $53.87 | 2024 | Spravato |
| Abbvie INC. | $50.95 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.33 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $44.62 | 2024 | Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $41.90 | 2024-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $37.52 | 2025 | Voquezna |
| Astellas Pharma US INC | $36.72 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $32.84 | 2024-2025 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.29 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ortho-Clinical Diagnostics, INC. | $26.79 | 2024 | Triage |
| Edwards Lifesciences Corporation | $23.69 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $21.05 | 2023 | |
| Medtronic, INC. | $18.76 | 2023 | Inpen Smart Insulin Delivery System |
| Amneal Pharmaceuticals LLC | $15.37 | 2024 | Unithroid |
| Seqirus USA INC | $14.94 | 2024 | Fluad, Flucelvax |
| Tactile Systems Technology INC | $13.94 | 2025 | Nimbl, Flexitouch Plus |
| Amgen INC. | $13.64 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.39 | 2024 | Synjardy, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.